Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Conditions
Brief summary
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with advanced soft tissue sarcoma. Vorinostat and bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vorinostat together with bortezomib may kill more tumor cells.
Detailed description
PRIMARY OBJECTIVES: I. To determine the objective response rate in patients with advanced soft tissue sarcoma treated with vorinostat and bortezomib. SECONDARY OBJECTIVES: I. Characterize the toxicity of this regimen in these patients. II. Evaluate the progression-free survival and median overall survival of patients treated with this regimen. OUTLINE: Patients receive vorinostat orally (PO) once daily on days 1-14. Patients also receive bortezomib intravenously (IV) over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up every 6 months for up to 2 years. (As of Addendum 7, patient follow-up no longer required.)
Interventions
DRUGvorinostat
400 mg given PO
DRUGbortezomib
1.3 mg/m\^2 given IV
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed advanced, unresectable, or metastatic soft tissue sarcoma (STS) * Measurable disease, defined as \>= 1 lesion that can be accurately measured in \>= 1 dimension as \>= 2 cm by conventional techniques OR \>= 1 cm by spiral computed tomography (CT) scan * No small round cell tumors, including the following: * Primitive neuroectodermal tumor * Rhabdomyosarcoma * Ewing sarcoma * Osteosarcoma * No known active and/or untreated brain metastases and/or brain metastases requiring ongoing therapy (e.g., corticosteroids) * Treated, inactive brain metastases not requiring ongoing therapy allowed provided the brain metastases have been stable for \>= 1 month as assessed by intracranial imaging AND there is no indication of increased vascularity of the treated metastases within 14 days before study entry as assessed by magnetic resonance imaging (MRI) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 OR Karnofsky PS 70-100% * Life expectancy \>= 12 weeks * Absolute neutrophil count (ANC) \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Total bilirubin normal * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =\< 2.5 times upper limit of normal * Creatinine normal OR creatinine clearance \>= 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to take oral medication * No peripheral neuropathy \>= grade 2 * No concurrent uncontrolled illness including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia or myocardial infarction within the past 6 months * Psychiatric illness and/or social situation that would limit compliance with study requirements * No history of Torsades de Pointes * No history of allergic reactions attributed to compounds of similar chemical or biological composition to vorinostat or bortezomib * No more than 1 prior systemic treatment for advanced STS, including investigational agents * Adjuvant therapy is not considered a systemic regimen * More than 2 weeks since prior valproic acid * More than 4 weeks since prior and no concurrent chemotherapy (\> 6 weeks for nitrosoureas or mitomycin C) or radiotherapy and recovered * Radiotherapy to bone metastasis within the past 2 weeks allowed provided there is active non-bone disease outside the radiation port * No prior radiotherapy to \>= 33% of the bone marrow * No prior vorinostat or bortezomib * No concurrent category I medications that are generally accepted to have a risk of causing Torsades de Pointes, including any of the following: * Quinidine, procainamide, disopyramide * Amiodarone, sotalol, ibutilide, dofetilide * Erythromycin, clarithromycin * Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide, cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine * No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients * No other concurrent investigational agents for the primary malignancy * No other concurrent anticancer therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Confirmed Tumor Responses | Up to 2 years | The number of confirmed tumor responses is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) on two consecutive evaluations at least six weeks apart. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest dimension (LD) of target lesions taking as reference the baseline sum LD. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | Up to 2 years | Progression-free survival is defined as the time from registration to the time of progression or death, whichever comes first. The distribution and median of progression-free survival times will be estimated using the method of Kaplan-Meier. |
| Overall Survival | Time from registration to death due to any cause, assessed up to 2 years | The distribution of survival time will be estimated using the method of Kaplan-Meier. |
Countries
United States
Participant flow
Recruitment details
Sixteen patients were accrued to this study from June 2009 through July 2010.
Pre-assignment details
One participant received commercial drug instead of study drug and was deemed a violation. Another participant did not have a post baseline measurement scan and by protocol is not evaluable for the primary endpoint. These patients were excluded from the primary endpoint analysis. Therefore, 14 participants were evaluated for each endpoint.
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Vorinostat, Bortezomib) Patients receive 400 mg vorinostat orally once daily on days 1-14. Patients also receive 1.3 mg/m\^2 bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 16 |
| Total | 16 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Protocol Violation | 2 |
Baseline characteristics
| Characteristic | Treatment (Vorinostat, Bortezomib) |
|---|---|
| Age, Continuous | 62 years |
| Region of Enrollment United States | 16 participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 16 / 16 |
| serious Total, serious adverse events | 6 / 16 |
Outcome results
Primary
Confirmed Tumor Responses
The number of confirmed tumor responses is defined as a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) on two consecutive evaluations at least six weeks apart. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest dimension (LD) of target lesions taking as reference the baseline sum LD.
Time frame: Up to 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Vorinostat, Bortezomib) | Confirmed Tumor Responses | Complete Response (CR) | 0 participants |
| Treatment (Vorinostat, Bortezomib) | Confirmed Tumor Responses | Partial Response (PR) | 0 participants |
Secondary
Overall Survival
The distribution of survival time will be estimated using the method of Kaplan-Meier.
Time frame: Time from registration to death due to any cause, assessed up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Vorinostat, Bortezomib) | Overall Survival | 16.4 months |
Secondary
Progression Free Survival
Progression-free survival is defined as the time from registration to the time of progression or death, whichever comes first. The distribution and median of progression-free survival times will be estimated using the method of Kaplan-Meier.
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Vorinostat, Bortezomib) | Progression Free Survival | 1.5 months |